A Phase 3 Study of MP-424 in Combination With Peginterferon Alfa-2b and Ribavirin, in Treatment-Naive Subjects With Genotype 1 Hepatitis C.
Phase of Trial: Phase III
Latest Information Update: 23 Mar 2017
At a glance
- Drugs Telaprevir (Primary) ; Peginterferon alfa-2b; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- Sponsors Mitsubishi Tanabe Pharma Corporation
- 07 Mar 2011 Actual end date (Aug 2010) added as reported by ClinicalTrials.gov.
- 07 Mar 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 28 Jan 2011 According to a Mitsubishi Tanabe Pharma Corporation, an application for the manufacturing and marketing approval of telaprevir for chronic hepatitis C has been submitted in Japan.